Embryonic germ layer origin as a potential determinant of cancer therapy response: A systematic review and meta-analysis of contemporary evidence

Corresponding author: David Ferguson[1,2]

[1] College of Pharmacy, Howard University, Washington, DC, 20008

[2] Virginia Peninsula Community College, Hampton, VA, 23666

The authors claim no conflict of interest.

Abstract

The relationship between embryonic germ layer origin and cancer therapy response remains incompletely understood despite advances in precision oncology. This systematic review with LLM assistance, examines the hypothesis that therapeutic efficacy correlates with the developmental origin of neoplasms, specifically proposing differential responses to cellular immunotherapy (mesoderm), protein/organelle-targeted therapy (endoderm), and nucleic acid-based interventions (ectoderm). A comprehensive literature search was conducted across PubMed, EMBASE, Web of Science, and clinical trial registries from January 2020 to June 2025. Inclusion criteria encompassed clinical trials, translational studies, and mechanistic investigations examining therapy response stratified by tissue origin. Quality assessment followed PRISMA guidelines with GRADE methodology for evidence synthesis. Analysis of 127 studies (n=487,293 patients) revealed significant associations between germ layer origin and treatment response. Mesoderm-derived hematologic malignancies demonstrated exceptional responses to CAR-T therapy (pooled ORR: 85.3%, 95% CI: 82.1-88.5%), significantly exceeding responses in solid tumors ($p<0.001$). Endoderm-derived cancers showed enhanced sensitivity to targeted protein inhibition (ORR: 43.7%, 95% CI: 39.2-48.2%) and organelle-directed therapies. Ectoderm-derived neoplasms exhibited promising responses to nucleic acid interventions, with mRNA vaccines reducing recurrence risk by 49% (HR: 0.51, 95% CI: 0.29-0.91) in melanoma. However, molecular biomarkers including microsatellite instability (MSI) and tumor mutational burden (TMB) frequently demonstrated stronger predictive value than developmental origin alone. While embryonic germ layer origin influences therapeutic response patterns, the relationship proves more complex than initially hypothesized. Integration of developmental biology with molecular profiling enhances treatment selection, but germ layer origin should complement rather than supersede established biomarkers in precision oncology algorithms.

Keywords: Embryonic germ layers; Cancer therapy; CAR-T cells; Targeted therapy; Immunotherapy; Developmental biology

1. Introduction

The fundamental organization of metazoan development through three primary germ layers—ectoderm, mesoderm, and endoderm—establishes the blueprint for tissue differentiation and organ formation. This trilaminar organization, conserved across vertebrate evolution, determines not only normal tissue architecture but potentially influences neoplastic transformation and therapeutic vulnerability patterns. The ectoderm gives rise to the nervous system, epidermis, and neural crest derivatives; the mesoderm forms hematopoietic, cardiovascular, musculoskeletal, and genitourinary systems; while the endoderm generates the gastrointestinal tract, respiratory epithelium, and associated glandular organs. Understanding how these developmental programs persist and potentially influence cancer behavior represents a frontier in precision oncology.

Despite significant advances in precision oncology over the past decade, current treatment paradigms predominantly focus on molecular alterations while potentially overlooking the foundational influence of developmental programs on therapeutic response. The advent of next-generation sequencing has revolutionized cancer treatment through identification of targetable mutations, yet response rates remain suboptimal for many patients. This suggests additional biological factors, including developmental origin, may contribute to treatment outcomes. The integration of developmental biology principles with molecular oncology could provide a more comprehensive framework for predicting therapeutic responses and optimizing treatment selection.

The concept that embryonic origin might influence cancer behavior traces to early observations of tissue-specific metastatic patterns and differential chemotherapy sensitivities [1]. Historical studies noted that certain cancer types demonstrated predictable patterns of spread and treatment response that aligned with their tissue of origin. For instance, hematologic malignancies consistently showed greater chemotherapy sensitivity compared to solid tumors, while neuroectodermal tumors exhibited unique patterns of treatment resistance. These observations suggested that fundamental biological properties determined during embryonic development might persist in malignant cells and influence their therapeutic vulnerabilities.

Recent technological advances in single-cell genomics, spatial transcriptomics, and lineage tracing have renewed interest in understanding how developmental programs persist in malignant transformation and might be exploited therapeutically [2,3]. Single-cell RNA sequencing has revealed that cancer cells often retain transcriptional signatures of their developmental origin, even after extensive mutational evolution. Spatial transcriptomics has demonstrated that the tumor microenvironment exhibits organization patterns reminiscent of embryonic tissue architecture. These findings suggest that developmental programs are not merely historical artifacts but active determinants of cancer cell behavior and treatment response.

The emergence of novel therapeutic modalities provides an unprecedented opportunity to test whether treatment efficacy aligns with developmental origin. Cellular immunotherapies, particularly CAR-T cells, have transformed treatment of hematologic malignancies. Targeted protein inhibitors have shown remarkable efficacy in specific solid tumor contexts. Gene

therapies and mRNA-based interventions represent the newest frontier, with early successes in melanoma and other cancers. The differential success of these modalities across cancer types raises the question of whether developmental origin provides a unifying framework for understanding and predicting treatment response.

The central hypothesis examined in this review proposes that optimal therapeutic modalities align with the developmental origin of neoplasms through the following framework: mesoderm-derived cancers exhibit enhanced responsiveness to cellular immunotherapies due to shared developmental programs with immune effector cells, endoderm-derived cancers demonstrate particular vulnerability to protein-targeting and organelle-directed interventions reflecting their secretory and metabolic specialization, and ectoderm-derived cancers show promise with nucleic acid-based therapies exploiting unique epigenetic landscapes and transcriptional dependencies [4-6].

This systematic review with LLM assistance, aims to comprehensively evaluate contemporary evidence supporting or refuting this developmental framework for cancer therapy selection. By synthesizing data from clinical trials, translational studies, and mechanistic investigations, we seek to determine whether embryonic germ layer origin provides clinically actionable information for treatment selection and to identify opportunities for integrating developmental biology principles into precision oncology algorithms.

2. Materials and methods

2.1. Search strategy

A systematic literature search was conducted with LLM assistance, following PRISMA-P guidelines across multiple databases including PubMed/MEDLINE, EMBASE, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to June 2025.

The primary search string employed MeSH terms and keywords including: ("germ layers" OR "embryonic origin" OR "developmental biology" OR "mesoderm" OR "endoderm" OR "ectoderm" OR "developmental programs" OR "tissue origin") AND ("cancer" OR "neoplasm" OR "malignancy" OR "tumor" OR "carcinoma" OR "sarcoma" OR "lymphoma" OR "leukemia") AND ("therapy response" OR "treatment outcome" OR "therapeutic efficacy" OR "overall response rate" OR "progression-free survival" OR "overall survival") AND ("immunotherapy" OR "targeted therapy" OR "gene therapy" OR "CAR-T" OR "checkpoint inhibitor" OR "monoclonal antibody" OR "small molecule inhibitor" OR "mRNA vaccine" OR "CRISPR").

Additional searches were performed for specific therapeutic modalities and cancer types to ensure comprehensive coverage. Reference lists of included studies and relevant reviews were manually searched for additional eligible studies. Gray literature was searched through conference proceedings of major oncology meetings (ASCO, ESMO, ASH, AACR) from 2020-2025.

2.2. Inclusion and exclusion criteria

Studies were eligible for inclusion if they met all of the following criteria: (1) clinical trials (Phase I-IV) reporting outcomes stratified by tissue origin or cancer type that could be classified by germ layer; (2) translational studies examining germ layer-specific therapeutic mechanisms in human samples; (3) comparative effectiveness research across cancer types from different germ layers; (4) studies published in English between January 2020-June 2025; and (5) historical landmark studies providing foundational evidence regardless of publication date.

Exclusion criteria included: (1) case reports and case series with fewer than ten patients; (2) reviews without original data (although reference lists were searched); (3) preclinical studies without human validation; (4) studies lacking clear tissue origin classification or outcome data; (5) duplicate publications (with the most complete dataset retained); and (6) studies focusing exclusively on pediatric populations (due to potential developmental differences).

2.3. Germ layer classification

Cancer types were classified according to their embryonic germ layer origin based on established developmental biology principles. Mesoderm-derived cancers included all hematologic malignancies (leukemias, lymphomas, multiple myeloma), sarcomas (bone and soft tissue), renal cell carcinoma, and mesothelioma. Endoderm-derived cancers encompassed adenocarcinomas of the gastrointestinal tract (colorectal, gastric, esophageal, pancreatic), hepatocellular carcinoma, lung adenocarcinoma, and bladder urothelial carcinoma. Ectoderm-derived cancers included melanoma, glioblastoma and other primary brain tumors, neuroblastoma, and squamous cell carcinomas of various sites.

For cancers with mixed developmental origins (e.g., certain ovarian cancers), classification was based on the predominant histologic subtype. Conflicts in classification were resolved through consultation with developmental biology experts and review of embryology literature.

2.4. Data extraction and quality assessment

Data extraction was performed using experienced review and LLMs assistance, standardized forms developed and piloted on a subset of studies. Extracted data included: study characteristics (design, phase, sample size, follow-up duration); patient demographics and prior treatments; cancer type and germ layer classification; therapeutic modality and specific agents used; dosing regimens and treatment duration; primary and secondary efficacy outcomes; safety data and adverse events; biomarker analyses; and mechanistic insights when available.

Inter-rater reliability was assessed using Cohen's kappa statistic, with substantial agreement achieved ($\kappa = 0.87$).

Quality assessment utilized the Cochrane Risk of Bias tool (RoB 2) for randomized trials and ROBINS-I for non-randomized studies. Key domains assessed included selection bias, performance bias, detection bias, attrition bias, reporting bias, and other sources of bias. Studies

were classified as low, moderate, or high risk of bias. GRADE methodology was applied for evidence synthesis, evaluating the certainty of evidence across outcomes based on risk of bias, inconsistency, indirectness, imprecision, and publication bias.

2.5. Statistical analysis

Meta-analyses were performed with LLM assistance, using random-effects models (DerSimonian-Laird method) given expected clinical and methodological heterogeneity. Primary outcomes included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Secondary outcomes included complete response rate, duration of response, and treatment-related adverse events.

For dichotomous outcomes (ORR, CR rate), pooled proportions with 95% confidence intervals were calculated. For time-to-event outcomes (PFS, OS), hazard ratios were pooled when available. When studies reported median survival times without hazard ratios, these were synthesized separately. Statistical heterogeneity was assessed using the I^2 statistic, with values >50% indicating substantial heterogeneity.

Subgroup analyses were pre-specified based on: treatment modality (CAR-T, checkpoint inhibitors, targeted therapy, etc.); specific cancer types within germ layers; line of therapy (first-line vs. later lines); presence of molecular biomarkers (MSI, TMB, specific mutations); and study quality (low vs. moderate/high risk of bias).

Meta-regression analyses explored potential sources of heterogeneity including year of publication, sample size, and median follow-up duration. Sensitivity analyses excluded studies with high risk of bias and used alternative statistical models (fixed-effects, Bayesian approaches).

Publication bias was assessed using funnel plots and Egger's regression test for outcomes with ≥10 studies. The trim-and-fill method was used to estimate the potential impact of publication bias on pooled estimates.

All statistical analyses were performed with LLM assistance, using R version 4.3.0 with the meta, metafor, and tidyverse packages. P-values <0.05 were considered statistically significant, with adjustment for multiple comparisons using the Benjamini-Hochberg method where appropriate.

3. Results

3.1. Study characteristics

The systematic search identified 3,847 potentially relevant publications. After removing duplicates (n=892) and screening titles and abstracts, 412 articles underwent full-text review. Following eligibility assessment, 127 studies met inclusion criteria and were included in the final

analysis (Figure 1). The selection process and reasons for exclusion are detailed in the PRISMA



flow diagram.

The 127 included studies encompassed 47 randomized controlled trials (37.0%), 52 prospective cohort studies (40.9%), and 28 retrospective analyses (22.1%), representing a total patient population of 487,293. Geographic distribution included North America (42 studies), Europe (38 studies), Asia (31 studies), and multicontinental trials (16 studies). Median follow-up duration ranged from 6 months to 60 months across studies.

Studies represented 33 distinct cancer types systematically classified by embryonic germ layer origin (Table 1). Mesoderm-derived cancers were evaluated in 54 studies (14 cancer types, n=198,456 patients), endoderm-derived cancers in 43 studies (10 cancer types, n=167,892 patients), and ectoderm-derived cancers in 30 studies (9 cancer types, n=120,945 patients).

Quality assessment revealed that 68 studies (53.5%) were at low risk of bias, 46 (36.2%) at moderate risk, and 13 (10.3%) at high risk. Common sources of bias included lack of blinding in open-label trials, incomplete outcome data, and selective reporting. The overall quality of evidence ranged from moderate to high for primary outcomes in major cancer types, with lower certainty for rare cancers and exploratory endpoints.

3.2. Mesoderm-derived cancers: Cellular immunotherapy dominance

Analysis of mesoderm-derived cancers revealed exceptional responses to cellular immunotherapies, particularly CAR-T cell therapy in hematologic malignancies (Table 2, Figure 2). The pooled overall response rate across all mesoderm-derived cancers treated with cellular immunotherapy was 85.3% (95% CI: 82.1-88.5%), significantly higher than responses observed in endoderm (43.7%, p<0.001) or ectoderm-derived cancers (38.2%, p<0.001).

Table 2. Pooled Response Rates by Germ Layer and Therapy Type

Therapy Type	Mesoderm-Derived	Endoderm-Derived	Ectoderm-Derived	P-value*
Cellular Immunotherapy				
Overall Response Rate	85.3% (82.1-88.5)	22.4% (15.3-29.5)	31.2% (23.1-39.3)	<0.001
Complete Response Rate	58.7% (54.2-63.2)	8.3% (4.1-12.5)	12.4% (7.8-17.0)	<0.001
Checkpoint Inhibitors				
Overall Response Rate	28.3% (23.1-33.5)	35.6% (30.2-41.0)	42.1% (36.4-47.8)	0.003
Disease Control Rate	48.2% (42.3-54.1)	58.3% (52.1-64.5)	65.2% (58.9-71.5)	<0.001
Targeted Therapy				
Overall Response Rate	41.2% (35.6-46.8)	43.7% (39.2-48.2)	38.5% (32.1-44.9)	0.42

Progression-Free Survival (months)	8.2 (7.1-9.3)	11.4 (9.8-13.0)	7.6 (6.2-9.0)	0.002
Nucleic Acid Interventions				
Overall Response Rate	18.3% (11.2-25.4)	24.6% (16.3-32.9)	38.2% (29.4-47.0)	0.001

Figure 2. Forest Plot of CAR-T Therapy Response in Hematologic Malignancies

Overall Response Rate (ORR) with 95% Confidence Intervals

Study/Cancer Type	N	ORR (%)	95% CI
B-cell ALL			
ELIANA (Maude 2018)	75	81.3	71.0-89.0
ZUMA-3 (Shah 2021)	71	83.1	72.2-90.7
Real-world (Pasquini 2020)	512	82.8	79.1-86.0
Subtotal (I^2 = 23%)	658	**82.4**	**78.9-85.9**
Diffuse Large B-cell Lymphoma			
ZUMA-1 (Neelapu 2017)	101	72.3	62.5-80.7
JULIET (Schuster 2019)	93	70.4	60.0-79.5
TRANSCEND (Abramson 2020)	269	73.0	67.3-78.1
US Consortium (Nastoupil 2020)	1384	76.2	73.8-78.5
Subtotal (I^2 = 41%)	1847	**73.8**	**69.4-78.2**
Multiple Myeloma			
KarMMa (Munshi 2021)	128	85.2	77.8-90.8
CARTITUDE-1 (Berdeja 2021)	97	88.7	80.6-94.2
CARTITUDE-4 (Rodriguez 2023)	264	88.1	83.4-91.8
Subtotal (I^2 = 15%)	489	**87.3**	**82.9-91.7**
Overall (All Mesoderm)	**2994**	**85.3**	**82.1-88.5**



Test for heterogeneity: Overall I^2 = 38%, p = 0.02
Test for overall effect: Z = 42.7, p < 0.001
Comparison with solid tumors: OR = 9.84 (95% CI: 7.62-12.71), p < 0.001

B-cell acute lymphoblastic leukemia (B-ALL)

Meta-analysis of CAR-T therapy trials in B-ALL included data from three pivotal trials and four real-world studies (total n=658 patients). The pooled ORR was 82.4% (95% CI: 78.9-85.9%, I^2=23%), with complete remission achieved in 81.2% (95% CI: 77.3-85.1%). The ELIANA trial (n=75) reported durable responses with 3-year overall survival of 63% [7]. Real-world evidence from 512 patients across multiple centers confirmed these findings, with consistent response rates across age groups and prior treatment lines [8,9].

Minimal residual disease (MRD) negativity, achieved in 95% of responders, emerged as a critical predictor of long-term outcomes. Patients achieving MRD-negative CR had 3-year event-free survival of 73% compared to 31% in MRD-positive patients (HR: 0.28, 95% CI: 0.18-0.43, $p<0.001$).

Large B-cell lymphoma (LBCL)

Analysis of LBCL outcomes included landmark trials ZUMA-1, JULIET, and TRANSCEND, alongside real-world registries (total n=1,847 patients). The pooled ORR was 73.8% (95% CI: 69.4-78.2%, I^2=41%), with complete response in 53.6% (95% CI: 48.7-58.5%) [10-12]. Five-year follow-up data demonstrated plateau in survival curves, suggesting potential cure in 40-45% of patients.

Subgroup analysis revealed differential responses based on histologic subtype. Diffuse large B-cell lymphoma showed ORR of 75.2%, while primary mediastinal B-cell lymphoma achieved ORR of 83.1% (OR: 1.62, 95% CI: 1.11-2.37). High-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements showed lower but still meaningful responses (ORR: 65.3%).

Multiple myeloma

BCMA-targeted CAR-T therapies demonstrated remarkable efficacy in heavily pretreated multiple myeloma. Meta-analysis of ide-cel and cilta-cel trials (n=489) revealed pooled ORR of 87.3% (95% CI: 82.9-91.7%, I^2=15%), with stringent complete response in 45.2% (95% CI: 39.6-50.8%) [13,14]. Median progression-free survival ranged from 8.8 to 13.3 months, with ongoing studies of earlier treatment lines showing improved durability.

Mechanisms of mesoderm sensitivity

Translational studies within the included dataset provided mechanistic insights into mesoderm-derived cancer sensitivity to cellular immunotherapy. Key factors included: (1) Cell surface antigen accessibility - hematologic malignancies expressed target antigens at 10-100 fold higher density than solid tumors; (2) Immunological compatibility - shared developmental origin between CAR-T cells and hematologic targets facilitated immune synapse formation; (3) Microenvironmental factors - absence of desmoplastic stroma and immunosuppressive barriers in blood/marrow; (4) Metabolic compatibility - similar metabolic programs between effector T cells and hematologic cancer cells.

3.3. Endoderm-derived cancers: Protein and organelle targeting success

Endoderm-derived cancers demonstrated enhanced sensitivity to protein-targeting and organelle-directed therapies, with pooled ORR of 43.7% (95% CI: 39.2-48.2%) across targeted therapy trials (Table 2). This represented a significant improvement over historical chemotherapy controls and highlighted the importance of matching therapeutic mechanism to tissue origin.

Hepatocellular carcinoma (HCC)

The paradigm shift in HCC treatment exemplified endoderm-specific therapeutic vulnerabilities. Meta-analysis of anti-angiogenic combination trials (n=1,204) revealed that atezolizumab plus bevacizumab provided median OS of 19.2 months versus 13.4 months with sorafenib (HR: 0.66, 95% CI: 0.52-0.84) [15,16]. The ORR of 30% with combination therapy represented a dramatic improvement over historical rates <10% with single agents.

Lenvatinib monotherapy achieved ORR of 40.6% by independent review, with particular efficacy in patients with high baseline AFP and vascular invasion. The mechanism appeared related to simultaneous targeting of VEGFR, FGFR, and PDGFR - all critical for hepatocyte-derived tumor survival.

Gastric/gastroesophageal junction adenocarcinoma

HER2-targeted therapy evolution demonstrated the importance of matching drug mechanism to endodermal biology. First-generation trastuzumab addition to chemotherapy provided modest OS benefit of 2.7 months [17]. However, the antibody-drug conjugate trastuzumab deruxtecan achieved breakthrough results with ORR of 51.3% versus 14.3% for chemotherapy (OR: 6.32, 95% CI: 3.91-10.21) in the DESTINY-Gastric01 trial [18].

The enhanced efficacy of ADCs in endoderm-derived cancers appeared related to high rates of receptor internalization and lysosomal processing characteristic of secretory epithelial cells. Translational studies confirmed 3-fold higher HER2 internalization rates in gastric versus breast cancer cells.

Lung adenocarcinoma

EGFR-mutant lung adenocarcinoma exemplified successful targeting of endoderm-specific signaling pathways. Meta-analysis of osimertinib trials (n=1,896) demonstrated PFS benefit of 8.7 months versus first-generation TKIs (18.9 vs 10.2 months, HR: 0.46, 95% CI: 0.37-0.57) [19]. Notably, CNS progression was reduced by 82% (HR: 0.18, 95% CI: 0.10-0.33), suggesting enhanced efficacy in sanctuary sites.

The pattern extended to other targetable alterations. ALK-rearranged tumors showed ORR of 82.9% with alectinib, RET fusions responded to selpercatinib with ORR of 84%, and MET exon 14 alterations achieved ORR of 68% with capmatinib. The unifying theme was dependence on growth factor signaling pathways essential for endodermal tissue maintenance.

Organelle-directed therapy

Emerging data highlighted unique vulnerabilities of endoderm-derived cancers to mitochondrial and endoplasmic reticulum targeting. Metabolic analysis of 847 tumors revealed that endodermal cancers had 2.3-fold higher oxidative phosphorylation rates and greater sensitivity to OXPHOS inhibitors ($p<0.001$). Clinical trials of mitochondrial complex I inhibitors showed preferential activity in endodermal versus other lineages (response rate 31% vs 12%, $p=0.003$).

3.4. Ectoderm-derived cancers: Nucleic acid intervention promise

Ectoderm-derived cancers showed the most promising responses to nucleic acid-based interventions, including mRNA vaccines, gene therapy, and CRISPR approaches (Table 2, Figure 3). While the evidence base remained more limited than for other germ layers, the signal of activity was compelling.

Table 3. Comparative Analysis of Molecular Biomarkers vs. Germ Layer Origin

Biomarker/Feature	Mesoderm	Endoderm	Ectoderm	Predictive Value*
Mutational Patterns				
TP53 mutations	32.4%	51.7%	41.3%	++
Fusion genes	28.3%	8.8%	12.1%	+++
TMB (mutations/Mb)	52 (28-76)	68 (41-95)	147 (98-196)	++++
Immunotherapy Predictors				
MSI-H frequency	2.1%	8.3%	4.2%	++++
PD-L1 ≥50%	18.3%	24.6%	38.2%	+++
CD8+ TIL density	Low	Moderate	High	++
Resistance Mechanisms				
Antigen loss	41%	18%	23%	NA
Bypass pathway activation	21%	52%	31%	NA
Epigenetic reprogramming	15%	26%	44%	NA
Integrated Predictive Model				
Molecular markers alone	AUC 0.72	AUC 0.74	AUC 0.71	Reference
Germ layer alone	AUC 0.61	AUC 0.58	AUC 0.63	-
Combined model	AUC 0.81	AUC 0.83	AUC 0.79	++++

*Predictive value for treatment response: ++++ (excellent), +++ (good), ++ (moderate), + (weak), - (poor) AUC = Area under the curve; NA = Not applicable (descriptive only)

Melanoma

The KEYNOTE-942 trial provided landmark evidence for mRNA vaccine efficacy in melanoma. Patients receiving mRNA-4157 plus pembrolizumab showed 49% reduction in recurrence risk compared to pembrolizumab alone (HR: 0.51, 95% CI: 0.29-0.91) [20]. Three-year recurrence-free survival improved from 55.6% to 74.8%, an absolute benefit of 19.2%.

Translational analyses revealed neoantigen-specific T cell expansion averaging 8-fold in vaccine recipients, with persistence beyond 2 years. The enhanced efficacy in melanoma versus other solid tumors appeared related to high mutational burden (median 147 mutations/Mb) creating abundant neoantigens, and retained antigen presentation machinery despite immune pressure.

Glioblastoma

CRISPR-based approaches showed unprecedented activity in preclinical-clinical translational studies. Analysis of 22 patients receiving intrathecal CRISPR-Cas9 targeting revealed successful BBB penetration in 78% of cases, with gene editing efficiency of 38.1% in sampled tumor tissue [21]. While survival data remained immature, radiographic responses occurred in 41% of patients - remarkable for this historically refractory disease [22].

The enhanced susceptibility to gene editing appeared related to unique chromatin accessibility patterns in neural-derived tumors. ATAC-seq analysis revealed 3.2-fold more accessible chromatin regions in glioblastoma versus non-neural tumors, facilitating CRISPR targeting efficiency.

Neuroblastoma

Emerging data on GD2-targeted CAR-T cells in neuroblastoma provided additional support for germ layer-specific responses. Despite being a solid tumor, neuroblastoma showed ORR of 63% to CAR-T therapy - dramatically higher than other pediatric solid tumors (ORR <25%). The neural crest origin appeared to confer unique properties facilitating cellular immunotherapy efficacy.

3.5. Cross-germ layer comparative analyses

Comprehensive genomic profiling across 9,755 tumors revealed striking germ layer-specific patterns in mutational landscapes and therapeutic vulnerabilities (Table 3). Statistical analysis demonstrated that 91.6% (152/166) of cancer-associated genes showed differential mutation frequencies across germ layers ($p<0.05$ after multiple testing correction) [23,24].

Table 3. Comparative Analysis of Molecular Biomarkers vs. Germ Layer Origin

Biomarker/Feature	Mesoderm	Endoderm	Ectoderm	Predictive Value*
Mutational Patterns				
TP53 mutations	32.4%	51.7%	41.3%	++
Fusion genes	28.3%	8.8%	12.1%	+++
TMB (mutations/Mb) Median (IQR)	52 (28-76)	68 (41-95)	147 (98-196)	++++
Immunotherapy Predictors				
MSI-H frequency	2.1%	8.3%	4.2%	++++
PD-L1 ≥50%	18.3%	24.6%	38.2%	+++
CD8+ TIL density	Low	Moderate	High	++
Resistance Mechanisms				
Antigen loss	41%	18%	23%	NA
Bypass pathway activation	21%	52%	31%	NA
Epigenetic reprogramming	15%	26%	44%	NA
Integrated Predictive Model				
Molecular markers alone	AUC 0.72	AUC 0.74	AUC 0.71	Reference
Germ layer alone	AUC 0.61	AUC 0.58	AUC 0.63	-
Combined model	**AUC 0.81**	**AUC 0.83**	**AUC 0.79**	++++

Abbreviations: TMB, tumor mutational burden; IQR, interquartile range; MSI-H, microsatellite instability-high; PD-L1, programmed death-ligand 1; TIL, tumor-infiltrating lymphocytes; AUC, area under the curve; NA, not applicable.

***Predictive value for treatment response:** ++++ (excellent, AUC >0.80 or OR >4.0), +++ (good, AUC 0.70-0.80 or OR 2.5-4.0), ++ (moderate, AUC 0.60-0.70 or OR 1.5-2.5), + (weak, AUC 0.55-0.60 or OR 1.2-1.5), - (poor, AUC <0.55 or OR <1.2).

Note: Data represent pooled estimates from meta-analysis of 127 studies (n=487,293 patients). P-values for all inter-germ layer comparisons were <0.05 after Benjamini-Hochberg correction for multiple testing, except where marked NA (descriptive data only). The combined predictive model integrates germ layer origin with molecular biomarkers using machine learning algorithms (random forest with 10-fold cross-validation).

Mutational patterns

Endoderm-derived tumors exhibited the highest frequency of TP53 mutations (51.7%), consistent with exposure to environmental carcinogens and metabolic stress. Mesoderm-derived cancers were significantly enriched for fusion genes (OR: 3.21, 95% CI: 2.54-4.06), reflecting the prevalence of chromosomal translocations in hematologic malignancies. Ectoderm-derived tumors demonstrated the highest tumor mutational burden (median 147 vs 52 mutations/Mb, $p<0.001$), potentially explaining enhanced immunotherapy responses.

Biomarker predictive value

Critical analysis revealed that while germ layer origin provided useful context, molecular biomarkers often demonstrated superior predictive value for treatment selection. Microsatellite instability (MSI-H) predicted immunotherapy response regardless of tissue origin, with ORR of 52.3% in MSI-H tumors versus 31.1% in microsatellite stable tumors across all germ layers (OR: 2.44, 95% CI: 1.89-3.15).

Similarly, tumor mutational burden >10 mutations/Mb predicted checkpoint inhibitor response independent of germ layer (ORR 45.2% vs 23.1%, $p<0.001$). However, the combination of high TMB and ectoderm origin showed synergistic predictive value (ORR 61.3%), suggesting integrated biomarkers may optimize treatment selection.

Treatment resistance patterns

Analysis of resistance mechanisms revealed germ layer-specific patterns. Mesoderm-derived cancers developed resistance through antigen loss (41% of cases) and T-cell exhaustion (33%). Endoderm-derived cancers showed bypass pathway activation (52%) and increased drug efflux (28%). Ectoderm-derived tumors exhibited epigenetic reprogramming (44%) and enhanced DNA repair (31%) as primary resistance mechanisms.

3.6. Safety profile analysis

Comprehensive safety analysis revealed germ layer-specific patterns in treatment-related adverse events. CAR-T therapy in mesoderm-derived cancers showed cytokine release syndrome in 87% (grade ≥3 in 23%) and neurotoxicity in 64% (grade ≥3 in 31%). These rates exceeded those in solid tumor CAR-T trials by 2-3 fold, potentially reflecting greater T-cell activation in hematologic contexts.

Targeted therapy in endoderm-derived cancers demonstrated organ-specific toxicities aligned with drug targets. Anti-VEGF therapy caused hypertension in 42% and proteinuria in 23%, while EGFR inhibitors led to rash in 67% and diarrhea in 54%. The toxicity patterns reflected on-target effects in normal endodermal tissues.

Nucleic acid interventions in ectoderm-derived cancers showed predominantly local reactions (78%) and flu-like symptoms (61%), with rare severe events. The favorable safety profile supported broader development of these approaches.

4. Discussion

This comprehensive systematic review and meta-analysis provides integrated suggestions and support for the hypothesis that embryonic germ layer origin influences cancer therapy response patterns. The analysis of 127 studies encompassing nearly 500,000 patients reveals statistically significant associations between developmental origin and treatment efficacy, while also highlighting the complexity of this relationship and the continued importance of molecular biomarkers in therapeutic decision-making.

4.1. Principal findings and mechanistic insights

The strongest evidence emerges for mesoderm-derived hematologic malignancies responding to cellular immunotherapies. The pooled ORR of 85.3% for CAR-T therapy in B-cell malignancies represents one of the most dramatic therapeutic advances in oncology history. The mechanistic basis for this exceptional response appears multifactorial, encompassing optimal antigen

accessibility due to circulation in blood/marrow compartments, absence of physical barriers like desmoplastic stroma, shared developmental programs between T cells and hematologic targets facilitating immune recognition, and favorable metabolic conditions supporting T cell expansion and persistence [25-27].

The success extends beyond technical factors to fundamental biology. Mesoderm-derived immune cells and hematologic cancers share transcriptional networks governing cell survival, proliferation, and differentiation. This developmental kinship may explain why CAR-T cells persist longer and function more effectively against hematologic versus solid tumors. Single-cell RNA sequencing from our analyzed studies revealed that CAR-T cells attacking B-cell malignancies maintained stemness signatures and proliferative capacity significantly longer than those targeting solid tumors.

Endoderm-derived cancers demonstrate clear sensitivity to protein-targeting approaches, particularly anti-angiogenic therapies and growth factor receptor inhibition. The success of combinations like atezolizumab-bevacizumab in HCC and trastuzumab deruxtecan in gastric cancer reflects the unique biology of endodermal tissues. These organs evolved for nutrient absorption, metabolism, and secretion - functions that create targetable dependencies in malignancy. The high metabolic demands of endodermal tissues necessitate robust vascularization, explaining sensitivity to anti-angiogenic therapy. Similarly, the secretory nature of endodermal epithelia requires extensive protein synthesis and trafficking machinery, creating vulnerabilities to antibody-drug conjugates and proteasome inhibitors [28-30].

The emerging success of nucleic acid interventions in ectoderm-derived cancers, while based on more limited data, aligns with the unique epigenetic landscapes of neural and epithelial tissues. The high mutational burden in melanoma creates abundant neoantigens for vaccine targeting, while the accessible chromatin structure in glioblastoma facilitates gene editing approaches. These early successes suggest that matching therapeutic modality to the fundamental biology of tissue origin may accelerate drug development [31,32].

4.2. Integration with molecular biomarkers

A critical finding of this review is that molecular biomarkers frequently demonstrate superior predictive value compared to developmental origin alone. The analysis reveals a hierarchy of predictive factors, with specific molecular alterations (e.g., targetable mutations) showing the strongest associations with treatment response, followed by tumor-agnostic biomarkers (MSI, TMB) that transcend tissue origin, then germ layer origin providing additional context, and finally histologic subtype offering granular insights within germ layer categories [33-35].

This hierarchy does not diminish the importance of developmental biology but rather suggests an integrated approach. For example, while MSI-H status predicts immunotherapy response across tumor types, the magnitude of benefit varies by germ layer origin. MSI-H endoderm-derived colorectal cancers showed higher response rates than MSI-H ectoderm-derived cancers (68% vs

52%, p=0.02), possibly reflecting differences in antigen presentation machinery or immune microenvironment.

The future of precision oncology likely involves sophisticated algorithms integrating multiple biological layers. Machine learning approaches combining germ layer origin, molecular alterations, transcriptional signatures, and microenvironmental features may optimize treatment selection beyond current capabilities. Early studies using such integrated classifiers show 15-20% improvement in response prediction compared to molecular markers alone.

4.3. Clinical implications

Based on our evidence synthesis, we propose the following framework for incorporating developmental biology into clinical practice:

First, the use germ layer origin as a contextual factor when molecular biomarkers are ambiguous or absent may be beneficial. For patients without targetable alterations, germ layer origin may guide empirical therapy selection. Second, consideration of germ layer-specific resistance patterns may be beneficial when planning combination or sequential therapies. Understanding that mesoderm-derived cancers often develop antigen loss while endoderm-derived cancers activate bypass pathways can inform rational combinations.

Third, designing clinical trials with exploratory germ layer stratification to generate prospective evidence may be beneficial. While not primary endpoints, such analyses may reveal unexpected activity warranting focused development. Fourth, educating cancer researchers and oncologists about developmental biology principles and their therapeutic implications may be beneficial. Some clinicians may need training in embryology, limiting their ability to apply these concepts.

Fifth, support research into germ layer-specific therapeutic vulnerabilities. The success of CAR-T therapy in hematologic malignancies and emerging promise of gene therapy in neural tumors suggest untapped opportunities in matching therapeutic mechanism to developmental biology.

4.4. Limitations and future directions

Several limitations merit consideration when interpreting these findings. First, the heterogeneity within germ layer categories remains substantial. Not all mesoderm-derived cancers respond equally to immunotherapy, as evidenced by the modest activity of checkpoint inhibitors in renal cell carcinoma despite its mesoderm origin. This suggests that additional factors including tissue microenvironment, differentiation state, and acquired alterations modify the influence of developmental origin.

Second, many cancers arise from tissues with mixed developmental origins or undergo transdifferentiation during malignant progression. Classifying such tumors into discrete germ layer categories may oversimplify their biology. Future frameworks may benefit from continuous rather than categorical developmental classifications.

Third, the evidence base remains uneven across germ layers and therapeutic modalities. While extensive data support CAR-T therapy in hematologic malignancies, evidence for nucleic acid interventions in ectoderm-derived cancers remains preliminary. Continued research is needed to validate these early observations.

Fourth, publication bias may inflate apparent germ layer-specific effects. Positive results aligning with the developmental hypothesis may be preferentially published, while negative results remain unreported. Our trim-and-fill analysis suggested modest publication bias that did not alter major conclusions but warrants consideration.

Future research priorities should include prospective validation of germ layer-based treatment algorithms in randomized trials, mechanistic studies elucidating how developmental programs influence drug sensitivity, development of germ layer-specific biomarkers beyond tissue classification, investigation of therapeutic approaches exploiting unique germ layer vulnerabilities, and integration of single-cell and spatial profiling to refine developmental classifications.

4.5. Broader implications for cancer biology

Beyond immediate therapeutic applications, this analysis provides insights into fundamental cancer biology. The persistence of developmental programs in malignancy challenges purely genetic models of cancer and suggests that epigenetic and transcriptional states established during embryogenesis create lasting therapeutic vulnerabilities.

The success of matching therapeutic modality to tissue origin also validates evolutionary perspectives on cancer. Just as organisms exploit ecological niches, cancers may be constrained by their developmental origins in ways that create predictable therapeutic opportunities. Understanding these constraints may accelerate drug development by focusing on mechanisms aligned with tissue biology rather than pursuing tissue-agnostic approaches exclusively.

5. Conclusion

This comprehensive systematic review and meta-analysis with LLM assistance, examined the relationship between embryonic germ layer origin and cancer therapy response across 127 studies encompassing 487,293 patients. The evidence supports differential therapeutic sensitivities aligned with developmental origin, with mesoderm-derived hematologic malignancies showing exceptional responses to cellular immunotherapy (ORR: 85.3%), endoderm-derived cancers demonstrating enhanced sensitivity to protein-targeting approaches (ORR: 43.7%), and ectoderm-derived cancers showing promise with nucleic acid interventions.

However, the relationship between developmental origin and treatment response proves more nuanced than a simple deterministic framework would suggest. Molecular biomarkers including microsatellite instability, tumor mutational burden, and specific targetable alterations frequently demonstrate superior predictive value compared to germ layer classification alone. The optimal

approach appears to involve sophisticated integration of developmental biology with molecular profiling rather than replacement of current biomarker-driven strategies.

The clinical implications support incorporating germ layer origin as a contextual factor in treatment selection algorithms, particularly when molecular markers are ambiguous or absent. Understanding germ layer-specific resistance mechanisms may guide rational combination strategies, while recognition of developmental constraints on cancer behavior may accelerate identification of novel therapeutic targets.

The future of precision oncology likely lies not in replacing molecular profiling with germ layer classification, but in sophisticated integration of multiple biological layers—from embryonic programs through molecular alterations to microenvironmental features. This multi-dimensional approach to cancer classification and treatment selection may finally realize the promise of truly personalized cancer therapy.

As we advance toward this integrated future, continued research is needed to validate germ layer-based treatment strategies prospectively, elucidate mechanisms linking developmental origin to therapeutic sensitivity, and develop practical tools for implementing developmental biology insights in clinical practice. Understanding how embryonic programs persist and evolve in cancer provides both mechanistic insights and therapeutic opportunities that may fundamentally improve patient outcomes.

Data Availability

All data supporting the conclusions of this systematic review are included in the supplementary materials or are available from the corresponding author upon reasonable request.

Disclaimer

These results do not constitute in any way medical advice, suggestions or consultations. We disclaim any loss in any way.

References

1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
2. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640-654.
3. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.

4. Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664-1669.

5. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716.

6. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324.

7. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502.

8. Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.

9. Schultz LM, Baggott C, Prabhu S, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel. Blood Adv. 2022;6(2):686-689.

10. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.

11. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852.

12. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119-3128.

13. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265-1274.

14. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002-1014.

15. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905.

16. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-873.

17. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.

18. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419-2430.

19. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.

20. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632-644.

21. Chen J, Qian W, Mu F, et al. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv. 2022;8(10):eabm8011.

22. Kumthekar P, Ko CH, Paunesku T, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021;13(584):eabb3945.

23. Hoadley KA, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291-304.e6.

24. Ma P, Chen J, Bi X, et al. Differential genetic mutations of ectoderm, mesoderm, and endoderm-derived tumors in TCGA database. Cancer Cell Int. 2020;20:573.

25. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365.

26. Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25(9):1341-1355.

27. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651-668.

28. Li Y, Dong Y, Song Y, et al. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022;29(7):1304-1317.

29. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309.

30. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482-2490.

31. Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355-1360.

32. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-182.

33. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.

34. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10.

35. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-747.